MorphoSys AG
Description MorphoSys AG, a biotechnology company, develops and commercializes therapeutic antibodies in North America, Europe, and Asia. Its partnered product pipeline comprises 70 human antibody drug candidates for the treatment of various diseases primarily, including Alzheimers, infectious, cardiovascular dysfunction, musculoskeletal, ophthalmology, autoimmune, and inflammation diseases. The companys proprietary therapeutic antibody candidates include MOR103 for rheumatoid arthritis and multiple sclerosis; MOR208 for the treatment of B cell malignancies and autoimmune diseases; and MOR202 for multiple myeloma and certain leukemias. The company has a strategic alliance with Novartis AG for the discovery and development of therapeutic antibodies. MorphoSys AG was founded in 1992 and is headquartered in Munich, Germany. To view the detailed information, you need to SUBSCRIBE with us. |
 |